Regencell Bioscience Holdings Limited (RGC) has experienced an extraordinary 23,745% stock price increase in 2025, reaching a market capitalization of $12 billion. This astronomical surge occurred despite the company reporting zero revenue, highlighting a significant decoupling from traditional fundamental metrics. The price action is primarily driven by tight float mechanics and an extended lock-up agreement involving the founder and his wife. A recent 35-for-1 reverse stock split and strategic SEC filings have further fueled the stock’s momentum as a high-profile meme stock. Analysts note that the restricted supply of shares has created a supply-demand imbalance, favoring continued upward price movement in the short term. While the lack of revenue presents extreme long-term risks, the current technical setup continues to attract intense speculative interest.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis